The Waddell lab uses genome-wide technologies to understand antimicrobial drug action during human disease, to define Mycobacterium tuberculosis populations that survive early drug therapy, and to identify the mode of action of novel anti-mycobacterial compounds. Our research also explores the interactions between host and pathogen throughout the disease process using transcriptional signatures derived from immune cells and bacteria to better explain tuberculosis pathogenicity, the emergence of antimicrobial drug resistance and to reveal novel treatment strategies. Simon Waddell trained in molecular microbiology at the University of Birmingham before completing a PhD in mycobacterial pathogenicity at St Georges, University of London. He then joined Stanford University as a postdoctoral scientist profiling host responses to infection. He moved to Brighton and Sussex Medical School, University of Sussex in 2010, where he is a Reader in Microbial Pathogenesis in the Department of Global Health and Infection.